Study of a drug combination for breast cancer that spread to the brain
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This trial tests whether a combination of three drugs (SHR-A1811, pyrotinib, and bevacizumab) can help people with advanced breast cancer that has spread to the brain. It aims to shrink brain tumors and stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced breast cancer with at least one untreated brain tumor seen on an MRI
- You are generally well enough to be up and about for at least half the day (ECOG score 0-2)
- Your major organs (like kidneys and liver) are working well
- You have not had whole-brain radiation, chemotherapy, or major surgery in the last 2 weeks
- You do not have certain severe lung diseases or bleeding problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SHR-A1811) combined with radiation therapy for people with HER2-positive or HER2-low breast cancer that has spread to the brain. It aims to see if the combination can better control brain metastases.
This trial tests whether SPH4336, added to standard hormone (endocrine) therapy, can improve outcomes for people with breast cancer that has spread to the brain. It also looks closely at safety and side effects.
This trial tests a combination of two drugs (SHR-A1921 and Avastin) to see if it can shrink or slow brain tumors caused by triple-negative breast cancer. It’s for people whose breast cancer has spread to the brain and haven’t had radiation to the brain yet.
This Phase 2 study tests a treatment for people with triple-negative breast cancer that has spread to the brain. It’s designed for situations where the cancer can’t be safely cured with surgery or focused radiation.
This trial tests a new drug SHR-A2102 combined with other treatments for advanced or metastatic breast cancer. It aims to see if the combination is safe and effective.
This study tests a combination of radiation therapy, chemotherapy drugs (platinum-based), and two immunotherapy medications (adebrelimab and bevacizumab) for triple-negative breast cancer that has spread to the brain. The goal is to shrink tumors and improve survival when surgery or standard radiation alone isn't an option.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.